<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 9-Oct | 6:00-7:00 AM          | Novel Cancer Therapeutics and Cancer Prevention                       | Multilevel Interventions in Cancer Prevention and Control: A Community-Based Translational Research Framework to Address Prostate Cancer Disparities                                                                  | Brian Rivers, PhD, MPH  
Director of the Cancer Health Equity Institute  
Morehouse School of Medicine (MSM)                                                             |
| 9-Oct | 7:30-8:30 AM          | Tumor Drug Resistance and Tumor Evolution                            | Keynote Presentation: Pairing protein profiling with drug screens uncovers an effective therapy against high risk leukemia                                                                                      | Ernesto Diaz-Flores, PhD  
Assistant Adjunct Professor in the Department of Pediatrics/Hematology at UCSF                       |
| 9-Oct | 9:00-10:00 AM         | Novel Cancer Therapeutics and Cancer Prevention                      | Start at the End: A Strategy for Developing and Delivering Advanced Diagnostic Tests to improve Prostate Cancer Patient Outcomes                                                                               | Stephen Pennington  
Professor of Proteomics, Founder, CEO and CSO Atturos Ltd.  
C/O UCD Conway Institute University College Dublin                                               |
| 9-Oct | 10:30-11:30 AM        | Tumor Drug Resistance and Tumor Evolution                            | A practical guide for multiplexed ion beam imaging to reveal tumor immunobiology                                                                                                                                  | Selena Ferriani  
Sr.Staff Scientist/LSRP3, Stanford University                                                   |
| 9-Oct | 10:30-11:30 AM        | Novel Cancer Therapeutics and Cancer Prevention                      | Newly Diagnosed Ovarian Cancer: Surgical Options                                                                                                                                                                 | Mitchel S. Hoffman, MD  
Full-time faculty member, Department of Gynecologic Oncology, Moffitt Cancer Center, and Professor, USF Morsani College of Medicine |
| 9-Oct | 12:00-1:00 PM         | Molecular Guidance Versus Standard of Care                            | Next Steps in Personalized Medicine- Using Genomics and Imaging For Treatment Selection in Early Stage Prostate Cancer                                                                                       | Anson Tharayanil  
Medical Science Liaison (Urology), Genomic Health, Inc.                                           |
| 9-Oct | 12:00-1:00 PM         | Novel Cancer Therapeutics and Cancer Prevention                      | What is New in Surgical Management of Invasive Bladder Cancer in 2020                                                                                                                                              | Khurshid Guru, MD  
Surgeon, Dept of Urology, Chair, Dept of Urology, Director, Applied Technology Laboratory for Advanced Surgery, Robert P. Huben Endowed Professor of Oncology, Roswell Park Cancer Institute |
| 9-Oct | 1:30-2:30 PM          | Tumor Drug Resistance and Tumor Evolution                            | Tumor processing for the isolation and visualization of Tumor Infiltrating Leukocytes                                                                                                                          | Josh Mahllos, PhD  
Senior Marketing Product Manager, Miltenyi Biotec                                                    |
| 10-Oct| 6:00-7:00 AM          | Novel Cancer Therapeutics and Cancer Prevention                      | Highly-efficient and -specific genome editing with Cas9 nickase ribonucleoproteins in Primary T-cells                                                                                                            | Jacob Lamberth  
R&D Scientist, Genome and Epigenome Editing: MilliporeSigma                                               |
| 10-Oct| 7:30-8:30 AM          | Novel Cancer Therapeutics and Cancer Prevention                      | Keynote Presentation: Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families                                                                               | Ernest Hawk, MD, MPH  
Vice President & Division Head for Cancer Prevention & Population Sciences, University of Texas MD Anderson Cancer Center |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Topic</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 10-Oct | 9:00-10:00 AM | Tumor Drug Resistance and Tumor Evolution | Dynamic evolution of unstable genomes: insights from in vitro experiments and cancer genome analysis | Cheng-Zhong Zhang, PhD  
Assistant Professor, Biomedical Informatics, Harvard Medical School; and Assistant Professor, Biostatistics & Computational Biology, Dana-Farber Cancer Institute |
| 10-Oct | 9:00-10:00 AM | Novel Cancer Therapeutics and Cancer Prevention | Next Generation Targets for Immuno-Oncology | Anthony Persen, PhD  
Sr. Director, Protein Business Unit, R&D Systems |
| 10-Oct | 10:30-11:30 AM | Molecular Guidance Versus Standard of Care | Transcriptional Profiling of the Pediatric Tumor Microenvironment | Troy McEachron, PhD  
Assistant Professor of Research, Translational Genomics, University of Southern California, Keck School of Medicine |
| 10-Oct | 10:30-11:30 AM | Tumor Drug Resistance and Tumor Evolution | Whole genome imaging for sensitive and accurate analysis of structural variations in cancer | Sven Bocklandt, PhD  
Director, Scientific Affairs, Bionano Genomics |
| 10-Oct | 12:00-1:00 PM | Tumor Drug Resistance and Tumor Evolution | Tumor Mutation Burden: Challenges and opportunities of measuring and interpreting tumor mutational burden for patient care | Ravindra Kolhe, MD, PhD  
Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC. |
| 10-Oct | 1:30-2:30 PM | Molecular Guidance versus Standard of Care | Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer | Tian Zhang, MD, MHS  
Assistant Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute |